<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">
Artículo 2026

Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges

Editorial
Endocrine reviews · Oxford University Press
Resumen

Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in which the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classic apparent mineralocorticoid excess (NC-AME) represents a prevalent and under recognized cause of cortisol-mediated mineralocorticoid receptor over activation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This review addresses that gap. NC-AME is formally defined as a syndrome of partial 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) insufficiency occurring in the absence of biallelic human HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The review consolidates evidence across 3 mechanistic domains, genetic and epigenetic dysregulation of HSD11B2 gene, endogenous and exogenous enzyme inhibition, and patient-specific alterations (ie, age, sex, renal function), and proposes a structured LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.

Estadísticas de uso

Página completa del ítem